Jean-Baptiste Rivière

Jean-Baptiste Rivière

Auto-generated profile, based on publicly available information

Jean-Baptiste Rivière

Department of Human Genetics, McGill University , 3640 rue University, Montreal, QC , H3A 0C7

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LALara Al-Olabi
Lara Al-Olabi
SPSatyamaanasa Polubothu
Satyamaanasa Polubothu
KDKatherine Dowsett
Katherine Dowsett
KAKatrina A. Andrews
Katrina A. Andrews
PSPaulina Stadnik
Paulina Stadnik
VKVeronica A. Kinsler
Veronica A. Kinsler
BACKGROUND. Sporadic vascular malformations (VMs) are complex congenital anomalies of blood vessels that lead to stroke, life-threatening bleeds, disfigurement, overgrowth, and/or pain. Therapeutic options are severely limited, and multidisciplinary management remains challenging, particularly for high-flow arteriovenous malformations (AVM). METHODS. To investigate the pathogenesis of sporadic intracranial and extracranial VMs in 160 children in which known genetic causes had been excluded, we sequenced DNA from affected tissue and optimized analysis for detection of low mutant allele frequency. RESULTS. We discovered multiple mosaic-activating variants in 4 genes of the RAS/MAPK pathway, KRAS, NRAS, BRAF, and MAP2K1, a pathway commonly activated in cancer and responsible for the germline RAS-opathies. These variants were more frequent in high-flow than low-flow VMs. In vitro characterization and 2 transgenic zebrafish AVM models that recapitulated the human phenotype validated the pathogenesis of the mutant alleles. Importantly, treatment of AVM-BRAF mutant zebrafish with the BRAF inhibitor vemurafinib restored blood flow in AVM. CONCLUSION. Our findings uncover a major cause of sporadic VMs of different clinical types and thereby offer the potential of personalized medical treatment by repurposing existing licensed cancer therapies. FUNDING. This work was funded or supported by grants from the AVM Butterfly Charity, the Wellcome Trust (UK), the Medical Research Council (UK), the UK National Institute for Health Research, the L’Oreal-Melanoma Research Alliance, the European Research Council, and the National Human Genome Research Institute (US).

6 July 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CTChristel Thauvin-Robinet
Christel Thauvin-Robinet
JLJaclyn S Lee
Jaclyn S Lee
ELEstelle Lopez
Estelle Lopez
VHVicente Herranz-Pérez
Vicente Herranz-Pérez
TSToshinobu Shida
Toshinobu Shida
MNMaxence V Nachury
Maxence V Nachury
Maxence Nachury, Christel Thauvin-Robinet and colleagues identify mutations in C2CD3 in two families with oral-facial-digital syndrome. They further show that C2CD3 localizes to the distal end of centrioles and acts as a positive regulator of centriole elongation. Centrioles are microtubule-based, barrel-shaped structures that initiate the assembly of centrosomes and cilia1,2. How centriole length is precisely set remains elusive. The microcephaly protein CPAP (also known as MCPH6) promotes procentriole growth3,4,5, whereas the oral-facial-digital (OFD) syndrome protein OFD1 represses centriole elongation6,7. Here we uncover a new subtype of OFD with severe microcephaly and cerebral malformations and identify distinct mutations in two affected families in the evolutionarily conserved C2CD3 gene. Concordant with the clinical overlap, C2CD3 colocalizes with OFD1 at the distal end of centrioles, and C2CD3 physically associates with OFD1. However, whereas OFD1 deletion leads to centriole hyperelongation, loss of C2CD3 results in short centrioles without subdistal and distal appendages. Because C2CD3 overexpression triggers centriole hyperelongation and OFD1 antagonizes this activity, we propose that C2CD3 directly promotes centriole elongation and that OFD1 acts as a negative regulator of C2CD3. Our results identify regulation of centriole length as an emerging pathogenic mechanism in ciliopathies.

9 May 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
UGUniversity of Washington Center for Mendelian Genomics
University of Washington Center for Mendelian Genomics
MTMichinori Toriyama
Michinori Toriyama
CLChanjae Lee
Chanjae Lee
STS Paige Taylor
S Paige Taylor
IDIvan Duran
Ivan Duran
JWJohn C Wallingford
John C Wallingford
John Wallingford and colleagues combine proteomics, in vivo imaging and genetic analyses to identify a new ciliopathy-associated protein module, which they call CPLANE. They show that CPLANE proteins, which include Fuzzy, Inturned and Wdpcp, interact with Jbts17 at basal bodies, where they act to recruit a specific subset of intraflagellar transport proteins. Cilia use microtubule-based intraflagellar transport (IFT) to organize intercellular signaling. Ciliopathies are a spectrum of human diseases resulting from defects in cilia structure or function. The mechanisms regulating the assembly of ciliary multiprotein complexes and the transport of these complexes to the base of cilia remain largely unknown. Combining proteomics, in vivo imaging and genetic analysis of proteins linked to planar cell polarity (Inturned, Fuzzy and Wdpcp), we identified and characterized a new genetic module, which we term CPLANE (ciliogenesis and planar polarity effector), and an extensive associated protein network. CPLANE proteins physically and functionally interact with the poorly understood ciliopathy-associated protein Jbts17 at basal bodies, where they act to recruit a specific subset of IFT-A proteins. In the absence of CPLANE, defective IFT-A particles enter the axoneme and IFT-B trafficking is severely perturbed. Accordingly, mutation of CPLANE genes elicits specific ciliopathy phenotypes in mouse models and is associated with ciliopathies in human patients.

31 January 2020 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
CSCAUSES Study
CAUSES Study
SNSophie Nambot
Sophie Nambot
LFLaurence Faivre
Laurence Faivre
GMGhayda Mirzaa
Ghayda Mirzaa
JTJulien Thevenon
Julien Thevenon
CTChristel Thauvin-Robinet
Christel Thauvin-Robinet
TBR1, a T-box transcription factor expressed in the cerebral cortex, regulates the expression of several candidate genes for autism spectrum disorders (ASD). Although TBR1 has been reported as a high-confidence risk gene for ASD and intellectual disability (ID) in functional and clinical reports since 2011, TBR1 has only recently been recorded as a human disease gene in the OMIM database. Currently, the neurodevelopmental disorders and structural brain anomalies associated with TBR1 variants are not well characterized. Through international data sharing, we collected data from 25 unreported individuals and compared them with data from the literature. We evaluated structural brain anomalies in seven individuals by analysis of MRI images, and compared these with anomalies observed in TBR1 mutant mice. The phenotype included ID in all individuals, associated to autistic traits in 76% of them. No recognizable facial phenotype could be identified. MRI analysis revealed a reduction of the anterior commissure and suggested new features including dysplastic hippocampus and subtle neocortical dysgenesis. This report supports the role of TBR1 in ID associated with autistic traits and suggests new structural brain malformations in humans. We hope this work will help geneticists to interpret TBR1 variants and diagnose ASD probands.

30 September 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
PVPierre Vabres
Pierre Vabres
ASArthur Sorlin
Arthur Sorlin
SKStanislav S. Kholmanskikh
Stanislav S. Kholmanskikh
BDBénédicte Demeer
Bénédicte Demeer
JSJudith St-Onge
Judith St-Onge
JRJean-Baptiste Rivière
Jean-Baptiste Rivière

8 July 2019 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
CLCamille Lemattre
Camille Lemattre
MIMarion Imbert-Bouteille
Marion Imbert-Bouteille
VGVincent Gatinois
Vincent Gatinois
PBPaule Benit
Paule Benit
ESElodie Sanchez
Elodie Sanchez
DGDavid Geneviève
David Geneviève
Early infantile epileptic encephalopathy (EIEE) is a heterogeneous group of severe forms of age-related developmental and epileptic encephalopathies with onset during the first weeks or months of life. The interictal electroencephalogram (EEG) shows a “suppression burst” (SB) pattern. The prognosis is usually poor and most children die within the first two years or survive with very severe intellectual disabilities. EIEE type 3 is caused by variants affecting function, in SLC25A22, which is also responsible for epilepsy of infancy with migrating focal seizures (EIMFS). We report a family with a less severe phenotype of EIEE type 3. We performed exome sequencing and identified two unreported variants in SLC25A22 in the compound heterozygous state: NM_024698.4: c.[813_814delTG];[818 G>A] (p.[Ala272Glnfs*144];[Arg273Lys]). Functional studies in cultured skin fibroblasts from a patient showed that glutamate oxidation was strongly defective, based on a literature review. We clustered the 18 published patients (including those from this family) into three groups according to the severity of the SLC25A22-related disorders. In an attempt to identify genotype–phenotype correlations, we compared the variants according to the location depending on the protein domains. We observed that patients with two variants located in helical transmembrane domains presented a severe phenotype, whereas patients with at least one variant outside helical transmembrane domains presented a milder phenotype. These data are suggestive of a continuum of disorders related to SLC25A22 that could be called SLC25A22-related disorders. This might be a first clue to enable geneticists to outline a prognosis based on genetic molecular data regarding the SLC25A22 gene.